Profile data is unavailable for this security.
About the company
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.
- Revenue in USD (TTM)11.68m
- Net income in USD-8.85m
- Incorporated2013
- Employees22.00
- LocationPulmatrix Inc36 Crosby Drive, Suite 100BEDFORD 01730United StatesUSA
- Phone+1 (781) 357-2333
- Fax+1 (302) 636-5454
- Websitehttps://www.pulmatrix.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cadrenal Therapeutics Inc | -100.00bn | -100.00bn | 6.71m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -16.10m | 6.83m | 8.00 | -- | 0.3437 | -- | -- | -14.03 | -14.17 | 0.00 | 19.06 | 0.00 | -- | -- | 0.00 | -49.97 | -- | -53.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.23 | -- | -- | -- |
| NLS Pharmaceutics AG | 0.00 | -12.17m | 6.86m | 3.00 | -- | -- | -- | -- | -0.3188 | -0.3188 | 0.00 | -0.2724 | 0.00 | -- | -- | 0.00 | -218.86 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -81.34 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
| Scorpius Holdings Inc | 2.23m | -46.05m | 6.86m | 77.00 | -- | 0.0749 | -- | 3.08 | -1.78 | -2.00 | 0.0859 | 1.39 | 0.0234 | -- | 0.6762 | 28,918.57 | -50.05 | -38.42 | -61.25 | -42.06 | 29.10 | -- | -2,136.28 | -703.02 | -- | -- | 0.2305 | -- | 202.12 | 33.24 | -23.85 | -- | 218.50 | -- |
| Cell MedX Corp | 70.00 | -96.91k | 6.90m | 0.00 | -- | -- | -- | 98,512.63 | -0.0029 | -0.0029 | 0.00 | -0.0024 | 0.0015 | -- | -- | -- | -202.28 | -792.55 | -- | -- | -685.71 | -- | -138,442.90 | -3,681.84 | -- | -3.17 | -- | -- | -54.53 | -- | 29.01 | -- | -- | -- |
| Tenax Therapeutics Inc | 0.00 | -10.10m | 6.97m | 5.00 | -- | 0.5609 | -- | -- | -24.52 | -24.52 | 0.00 | 6.35 | 0.00 | -- | -- | 0.00 | -67.96 | -199.16 | -75.66 | -285.64 | -- | -- | -- | -- | -- | -105.12 | 0.0322 | -- | -- | -- | 30.21 | -- | -- | -- |
| Longeveron Inc | 978.00k | -21.62m | 7.11m | 23.00 | -- | 0.9275 | -- | 7.27 | -9.58 | -9.58 | 0.4297 | 1.21 | 0.0621 | -- | 7.14 | 42,521.74 | -132.19 | -63.15 | -184.16 | -75.68 | 48.47 | 33.70 | -2,129.24 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| Kazia Therapeutics Ltd (ADR) | 14.90k | -13.52m | 7.12m | 12.00 | -- | 0.7734 | -- | 477.59 | -0.82 | -0.82 | 0.0008 | 0.3491 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
| Pulmatrix Inc | 11.68m | -8.85m | 7.16m | 22.00 | -- | 0.3764 | -- | 0.6127 | -2.42 | -2.42 | 3.20 | 5.21 | 0.3517 | -- | 17.84 | 531,090.90 | -26.63 | -46.91 | -30.21 | -58.12 | -- | -- | -75.73 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -6.59m | 7.16m | 8.00 | -- | 1.69 | -- | -- | -0.441 | -0.441 | 0.00 | 0.2524 | 0.00 | -- | -- | 0.00 | -90.28 | -- | -104.75 | -- | -- | -- | -- | -- | -- | -49.56 | 0.1527 | -- | -- | -- | -112.71 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 2.83m | -10.03m | 7.18m | 17.00 | -- | 0.6033 | -- | 2.54 | -64.14 | -64.14 | 4.60 | 3.82 | 0.2041 | 2.69 | 7.77 | 166,299.40 | -72.67 | -80.65 | -107.67 | -224.84 | 23.33 | -- | -356.09 | -948.54 | 1.87 | -- | 0.0451 | -- | 187.51 | 367.97 | -28.00 | -- | -- | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 7.27m | 389.00 | 0.0013 | 0.0001 | 0.7877 | 0.1276 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
| Notable Labs Ltd | 311.00k | -12.39m | 7.30m | 16.00 | -- | 0.6327 | -- | 23.49 | -2.31 | -2.31 | 0.0622 | 1.28 | 0.0142 | -- | -- | 19,437.50 | -56.70 | -52.02 | -74.10 | -62.09 | 37.30 | 60.19 | -3,984.24 | -3,636.93 | -- | -- | 0.0271 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| Protagenic Therapeutics Inc | 0.00 | -6.01m | 7.41m | -- | -- | 3.47 | -- | -- | -1.37 | -1.37 | 0.00 | 0.4808 | 0.00 | -- | -- | -- | -117.26 | -74.49 | -140.56 | -92.56 | -- | -- | -- | -- | -- | -11.50 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| NuCana PLC (ADR) | 0.00 | -33.78m | 7.44m | 25.00 | -- | -- | -- | -- | -301.88 | -301.88 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -72.34 | -41.01 | -125.17 | -48.07 | -- | -- | -- | -- | -- | -- | 0.0324 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
| Trevena Inc | 3.14m | -40.15m | 7.65m | 23.00 | -- | -- | -- | 2.44 | -2.71 | -2.71 | 0.2107 | -0.7999 | 0.0904 | -- | -- | 136,478.30 | -115.65 | -55.93 | -148.14 | -66.35 | 48.04 | -- | -1,279.01 | -3,134.41 | -- | -15.39 | 1.88 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
Data as of May 23 2024. Currency figures normalised to Pulmatrix Inc's reporting currency: US Dollar USD
6.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Mar 2024 | 114.82k | 3.14% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 54.90k | 1.50% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 35.08k | 0.96% |
| Geode Capital Management LLCas of 31 Mar 2024 | 24.66k | 0.68% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 13.95k | 0.38% |
| Tower Research Capital LLCas of 31 Mar 2024 | 5.21k | 0.14% |
| TD Waterhouse Canada, Inc.as of 31 Mar 2024 | 350.00 | 0.01% |
| American Portfolios Advisors, Inc.as of 31 Mar 2024 | 175.00 | 0.01% |
| UBS Financial Services, Inc.as of 31 Mar 2024 | 165.00 | 0.01% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 2024 | 113.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
